⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
AGE-RAGE Pathway in Aging and Neurodegeneration
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-28 — Rosiglitazone alleviates Parkinson’s disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway.: Drosophila PD model: rosiglitazone (a PPARγ agonist) and its elevated downstream metabolite dCTP alleviated PD phenotypes by inhibiting over-activated AGE-RAGE/EGR1 signaling, reducing lipid-droplet accumulation and restoring mitochondrial quality control — fly-only metabolomic/transcriptomic evidence nominating AGE-RAGE as a druggable node for repositioning a diabetes drug in neurodegeneration. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Rosiglitazone alleviates Parkinson's disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway.
28-may-2026
novelty 3
per-area 3
strengthens